Collegium Pharmaceutical (COLL) Receivables - Net (2016 - 2026)

Collegium Pharmaceutical's Receivables - Net history runs 11 years deep, the most recent figure standing at $228.8 million for Q1 2026.

• In Q1 2026, Receivables - Net changed 0.02% year-over-year to $228.8 million; the TTM figure through Mar 2026 stood at $228.8 million (changed 0.02% YoY), while the FY2025 annual figure was $211.3 million, down 7.53% from the prior year.
• Receivables - Net was $228.8 million for Q1 2026 at Collegium Pharmaceutical, up from $211.3 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $233.9 million in Q3 2025 to a low of $166.3 million in Q1 2022.
• Historically, Receivables - Net has averaged $198.9 million across 5 years, with a median of $195.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net surged 119.21% in 2022, then retreated 15.2% in 2023.
• A 5-year view of Receivables - Net shows it stood at $183.1 million in 2022, then declined by 1.96% to $179.5 million in 2023, then gained by 27.3% to $228.5 million in 2024, then retreated by 7.53% to $211.3 million in 2025, then climbed by 8.25% to $228.8 million in 2026.
• The last three Receivables - Net figures came in at $228.8 million (Q1 2026), $211.3 million (Q4 2025), and $233.9 million (Q3 2025), per Business Quant data.